An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidat

  • Markowitz, Avi, (PI)

    Project: Other project

    StatusFinished
    Effective start/end date3/22/166/30/18

    Funding

    • Novartis Pharmaceuticals Corporation: $6,153.85